Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.

Hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. However, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. The investigators routinely use a standardized deresuscitation protocol in patients with fluid overload and continuous renal replacement therapy combined with monitoring of clinical and biological perfusion parameters.

The aim of the study was to describe perfusion during deresuscitation, and to determine whether it is associated with major adverse kidney events at day 30.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fluid Overload Acute Kidney Injury Continuous Renal Replacement Therapy Edema Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathological Conditions, Signs and Symptoms Renal Insufficiency Signs and Symptoms Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Louis Pradel Hospital

France, Bron, 69500

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years old
Acute kidney injury requiring continuous renal replacement therapy
Standardized deresuscitation following a routine care protocol

Exclusion criteria

Chronic hemodialysis
Advanced directives to withhold or withdraw life-sustaining treatment,
Patient's opposition to the use of his/her personal health data

Treatment and study plan

Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.

Other

Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.

Primary outcomes

MAKE 30

Time frame: A day 30 after the initiation of the deresuscitation strategy
Major adverse kidney event at day 30, defined as follows:
- Death OR
- No weaning of renal replacement therapy OR
- Serum creatinine > 2 times baseline serum creatinine

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: DeepCART

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Mar 28, 2025
Registry last updated: Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed